Developing new precision tools for early detection and treatment


To develop new precision tools for early detection and precision treatment of cancer, neurological disorders, cardiovascular diseases, inflammatory conditions, infection, and chronic pain syndromes. Imaging using radiopharmaceuticals that can target and track changes at a molecular level, combined with the ability to turn these diagnostic tools into treatments called theragnostics (diagnostics + therapy), are the most advanced tools to get us there.




  • generates clinically approved and novel radiotracers to advance early detection and treatment of diseases
  • >40 different radiopharmaceuticals are produced at the CRF
  • >36 under FDA-approved INDs or RDRC approvals



  • Supports the efforts of over 20 faculty within the Department of Radiology
  • Supports over 25 faculty from other departments including Medicine, Neurology, Pediatrics, Pathology, Psychiatry, Radiation Oncology, Surgery.
  • The data generated by such research has helped support numerous research grants over the years (up to $29M in NIH funds).



The CRF staff members provide formal training in

  • radiation safety
  • radiolabeling chemistry
  • quality control for translation to human studies